233 related articles for article (PubMed ID: 3882737)
1. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.
Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO
J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
5. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
Thorner MO; Martin WH; Rogol AD; Morris JL; Perryman RL; Conway BP; Howards SS; Wolfman MG; MacLeod RM
J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
[TBL] [Abstract][Full Text] [Related]
7. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
Lamberts SW; Verleun T; Oosterom R
Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
[TBL] [Abstract][Full Text] [Related]
8. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
Brue T; Lancranjan I; Louvet JP; Dewailly D; Roger P; Jaquet P
Fertil Steril; 1992 Jan; 57(1):74-80. PubMed ID: 1730334
[TBL] [Abstract][Full Text] [Related]
9. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
[TBL] [Abstract][Full Text] [Related]
10. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen.
Prior JC; Cox TA; Fairholm D; Kostashuk E; Nugent R
J Clin Endocrinol Metab; 1987 Feb; 64(2):391-4. PubMed ID: 3793856
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.
Halperin I; Rodriguez MD; Cardenal C; Casamitjana R; Martinez Osaba MJ; Lienas V; Vilardell E
J Endocrinol Invest; 1987 Jun; 10(3):277-82. PubMed ID: 3040850
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.
Warfield A; Finkel DM; Schatz NJ; Savino PJ; Snyder PJ
Ann Intern Med; 1984 Dec; 101(6):783-5. PubMed ID: 6497193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas.
Essaïs O; Bouguerra R; Hamzaoui J; Marrakchi Z; Hadjri S; Chamakhi S; Zidi B; Ben Slama C
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):524-31. PubMed ID: 12527854
[TBL] [Abstract][Full Text] [Related]
14. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
15. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
16. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland.
Esiri MM; Bevan JS; Burke CW; Adams CB
J Clin Endocrinol Metab; 1986 Aug; 63(2):383-8. PubMed ID: 3722328
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect.
Coculescu M; Simionescu N; Oprescu M; Alessandrescu D
Endocrinologie; 1983; 21(3):157-68. PubMed ID: 6635518
[TBL] [Abstract][Full Text] [Related]
18. [Bromocriptine treatment of hyperprolactinemia].
Gauer J; Heberling HJ; Stubert B; Richardt W; Lohmann D
Z Gesamte Inn Med; 1985 Jul; 40(13):393-6. PubMed ID: 4036221
[TBL] [Abstract][Full Text] [Related]
19. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
Tyson D; Reggiardo D; Sklar C; David R
Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
[TBL] [Abstract][Full Text] [Related]
20. Extrasellar prolactinomas: successful management of 24 patients using bromocriptine.
Sieck JO; Niles NL; Jinkins JR; Al-Mefty O; el-Akkad S; Woodhouse N
Horm Res; 1986; 23(3):167-76. PubMed ID: 3949288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
